Business Description
ESSA Pharma Inc
NAICS : 325412
SIC : 3741
ISIN : CA29668H7085
Description
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 385.29 | |||||
| Equity-to-Asset | 0.97 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 12.3 | |||||
| 3-Year EPS without NRI Growth Rate | 7 | |||||
| 3-Year FCF Growth Rate | 8.1 | |||||
| 3-Year Book Growth Rate | -14 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.77 | |||||
| 9-Day RSI | 27.37 | |||||
| 14-Day RSI | 26.05 | |||||
| 6-1 Month Momentum % | -62.27 | |||||
| 12-1 Month Momentum % | -73.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 38.64 | |||||
| Quick Ratio | 38.64 | |||||
| Cash Ratio | 38.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | -0.31 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -21.2 | |||||
| ROA % | -20.62 | |||||
| ROIC % | -2716.34 | |||||
| ROC (Joel Greenblatt) % | -10304.33 | |||||
| ROCE % | -21.17 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.58 | |||||
| Price-to-Tangible-Book | 0.58 | |||||
| EV-to-EBIT | 1.94 | |||||
| EV-to-EBITDA | 1.95 | |||||
| EV-to-FCF | 2.38 | |||||
| Price-to-Net-Current-Asset-Value | 0.58 | |||||
| Price-to-Net-Cash | 0.58 | |||||
| Earnings Yield (Greenblatt) % | 51.55 | |||||
| FCF Yield % | -31.4 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EPIX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ESSA Pharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.64 | ||
| Beta | 1.91 | ||
| Volatility % | 87.53 | ||
| 14-Day RSI | 26.05 | ||
| 14-Day ATR ($) | 0.110301 | ||
| 20-Day SMA ($) | 1.683 | ||
| 12-1 Month Momentum % | -73.05 | ||
| 52-Week Range ($) | 1.4 - 11.67 | ||
| Shares Outstanding (Mil) | 44.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ESSA Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ESSA Pharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ESSA Pharma Inc Frequently Asked Questions
What is ESSA Pharma Inc(EPIX)'s stock price today?
The current price of EPIX is $1.61. The 52 week high of EPIX is $11.67 and 52 week low is $1.40.
When is next earnings date of ESSA Pharma Inc(EPIX)?
The next earnings date of ESSA Pharma Inc(EPIX) is 2025-02-13 Est..
Does ESSA Pharma Inc(EPIX) pay dividends? If so, how much?
ESSA Pharma Inc(EPIX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers